- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.07. | Taiho exercises option for Arcus Biosciences' quemliclustat in Asia | 4 | Pharmaceutical Technology | ||
| 08.07. | Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences | 1 | Benzinga.com | ||
| 03.06. | Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study | 8 | Zacks | ||
| 03.06. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.05. | Arcus Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.05. | Earnings call: Arcus Biosciences Reports Strong Q1 2024 Performance | 4 | Investing.com | ||
| 08.05. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update | 94 | Business Wire | HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies... ► Artikel lesen | |
| 25.03. | Navigating 5 Analyst Ratings For Arcus Biosciences | 2 | Benzinga.com | ||
| 20.03. | Arcus Biosciences COO sells over $240k in company stock | 5 | Investing.com | ||
| 22.02. | Earnings call: Arcus Biosciences reports strong Q4 results, plans for 2025 | 6 | Investing.com | ||
| 22.02. | Arcus Biosciences GAAP EPS of -$1.08 misses by $0.06, revenue of $31M beats by $2.7M | 2 | Seeking Alpha | ||
| 21.02. | Arcus Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 21.02. | Arcus Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 21.02. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.02. | Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update | 196 | Business Wire | HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies... ► Artikel lesen | |
| 20.02. | Arcus Biosciences Q4 2023 Earnings Preview | 2 | Seeking Alpha | ||
| 19.02. | Zimberelimab by Arcus Biosciences for Extrahepatic Bile Duct Cancer: Likelihood of Approval | 2 | Pharmaceutical Technology | ||
| 19.02. | Zimberelimab by Arcus Biosciences for Metastatic Colorectal Cancer: Likelihood of Approval | 2 | Pharmaceutical Technology | ||
| 19.02. | Zimberelimab by Arcus Biosciences for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval | 5 | Pharmaceutical Technology |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,650 | +3,83 % | EQS-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024 | EQS-Ad-hoc: Epigenomics AG / Schlagwort(e): Halbjahresergebnis
Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024
22.07.2024 / 17:49 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 52,75 | -1,40 % | Is a Beat in the Cards for CRISPR Therapeutics (CRSP) in Q2 Earnings? | ||
| REGENERON PHARMACEUTICALS | 997,00 | +2,15 % | Regeneron (REGN) to Report Q2 Earnings: What's in the Cards? | ||
| DEFENCE THERAPEUTICS | 0,556 | +2,96 % | EQS-News: Defence Therapeutics Inc.: Defence Therapeutics erhält Unterstützung durch das CNRI-H-Projekt von Canadian Nuclear Laboratories zur Beschleunigung der Entwicklung seines Radioimmunokonjugat-Programms | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
DEFENCE THERAPEUTICS ERHÄLT UNTERSTÜTZUNG DURCH DAS CNRI-H-PROJEKT VON CANADIAN NUCLEAR LABORATORIES... ► Artikel lesen | |
| EXELIXIS | 21,500 | -0,14 % | Exelixis Resolves Two CABOMETYX Patent Disputes With Cipla | NEW DELHI (dpa-AFX) - Exelixis, Inc. (EXEL) announced Monday that it has entered into a Settlement and License Agreement with Cipla Ltd. and Cipla USA, Inc. to resolve two patent litigations... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,316 | -7,60 % | Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards? | ||
| BEAM THERAPEUTICS | 33,140 | +3,02 % | Beam Therapeutics Stock Earns RS Rating Jump To 85 | ||
| ONCOLYTICS BIOTECH | 0,935 | 0,00 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights | Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET
SAN DIEGO, Calif. and CALGARY, Alberta, July 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,350 | +3,73 % | DelveInsight Business Research, LLP: Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics | Vascular malformations represent one of the largest and most underserved segments. The current Atreatment options are limited. The market size of vascular malformations is expected to increase... ► Artikel lesen | |
| ASSERTIO | 1,505 | +2,38 % | Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024 | ||
| ARCTURUS THERAPEUTICS | 24,030 | +4,57 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs | ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,700 | +0,38 % | Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark | ||
| SIGA TECHNOLOGIES | 10,520 | +5,09 % | SIGA Technologies Inc.: SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,160 | +0,61 % | ADMA BIOLOGICS, INC. - 8-K, Current Report |
Das Unternehmen ARCUS BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +5,64 % bei einem Aktienkurs von 15,820 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.
